1 H. Lee Moffitt Cancer Center and Research Institute , Tampa, Florida.
J Womens Health (Larchmt). 2014 Feb;23(2):184-8. doi: 10.1089/jwh.2013.4517. Epub 2013 Nov 21.
Although relative survival for breast cancer has improved in recent years, patients who present with metastatic disease have a less than 30% 5-year survival. Thus, improvements in treatment for these patients have the potential to have a significant impact on outcomes. Historically, removal of the primary breast tumor has been offered to these patients only for palliation. However, there have been recent reports that removal of the primary tumor may improve survival. Here, we review the theories and data at the center of the debate, the landmark studies that historically guided treatment, the retrospective data that revisited the role of removal of the primary tumor, as well as the latest advances in basic science and the accruing clinical studies to provide for future directions in this field. Although the definitive role of removal of the primary tumor in metastatic breast cancer is not settled, it is critical to understand the complexities of this debate in order to make further gains in breast cancer survivorship.
尽管近年来乳腺癌的相对存活率有所提高,但患有转移性疾病的患者的 5 年存活率不足 30%。因此,改善这些患者的治疗方法有可能对结果产生重大影响。从历史上看,仅为缓解症状才向这些患者提供原发性乳腺癌肿瘤切除术。但是,最近有报道称,切除原发性肿瘤可能会提高生存率。在这里,我们回顾了争论的核心理论和数据,具有历史意义的指导治疗的标志性研究,重新探讨原发性肿瘤切除术作用的回顾性数据,以及基础科学的最新进展和正在进行的临床研究,为该领域的未来发展方向提供了依据。尽管原发性肿瘤切除术在转移性乳腺癌中的明确作用尚未确定,但了解这一争论的复杂性对于进一步提高乳腺癌患者的生存率至关重要。